Trial Profile
An Open-label, Randomized, Controlled Phase III Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors SynCore Biotechnology
- 24 Apr 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2027.
- 24 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2025.
- 06 Dec 2022 Status changed from recruiting to suspended.